Taxol dose intensification and its clinical implications

G Sarosy, E Reed, G Sarosy, E Reed

Abstract

Taxol is the most exciting new anticancer agent developed in the past two decades. Of great interest is its level of activity in ovarian cancer, as well as substantial activity in breast cancer, nonsmall-cell lung cancer, melanoma, and other malignancies. Recent studies suggest that when taxol is administered in a fashion to increase milligram dosage per unit time (mg/m2/week), the response rate in patients with ovarian cancer is markedly increased. This article reviews studies that suggest taxol dose intensity is important in the treatment of patients with ovarian cancer.

References

    1. Neurology. 1989 Mar;39(3):368-73
    1. Cancer Invest. 1991;9(2):133-6
    1. J Clin Oncol. 1991 Sep;9(9):1704-12
    1. J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805
    1. Cancer Treat Rep. 1987 Dec;71(12):1171-7
    1. J Clin Oncol. 1987 Aug;5(8):1232-9
    1. Cancer Res. 1987 May 1;47(9):2486-93
    1. Ann Intern Med. 1989 Aug 15;111(4):273-9
    1. Cancer Res. 1989 Aug 15;49(16):4640-7
    1. J Clin Oncol. 1992 Jan;10(1):1-2
    1. J Natl Cancer Inst. 1990 Aug 1;82(15):1247-59

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj